ITCC-067 Quizartinib

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

ITCC-067 Quizartinib

A phase I/II, multi-center, dose-escalating study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of Quizartinib administered in combination with re-induction chemotherapy, and as a single-agent maintenance therapy

Promotor Name : Daiichi Sankyo, Inc

Investigator Name : M. ZWAAN

Trial registered on : NCT03793478